News

OKLAHOMA CITY, OK (April 26, 2010)– Cytovance Biologics, LLC and Selexys Pharmaceutical Corporation jointly announce an agreement and execution of a Biopharmaceutical Development and Manufacturing collaboration for their Anti-PSGL-1 therapeutic agent.  This monoclonal antibody (mAb) is being developed for treatment of inflammation associated with Crohn’s disease as a lead indication. 

Under the scope of this agreement, Cytovance will spearhead the cell culture process optimization, recovery and purification development, CGMP manufacturing as well as technical and regulatory support to facilitate Selexys’ clinical program.  Anti-PSGL-1 mAb will be manufactured at Cytovance’s 44,000 sq. ft. production facility that was custom-designed for multi-product CGMP manufacturing and meets US and EU regulatory standards.

“Our development and manufacturing collaboration extends our strategic partnership with Cytovance as they have demonstrated on time execution of our first antibody for sickle cell disease.  We look forward to this continued alliance as we work together towards advancing this important therapy to patients who suffer from Crohn’s”, said Scott Rollins, President and CEO, Selexys Pharmaceutical Corporation.  “We are pleased that Selexys has once again chosen Cytovance to work in concert as their development and manufacturing partner”, said Darren Head, President and CEO of Cytovance Biologics.  “This agreement confirms our shared commitment to highlight the biotechnology life science sector in Oklahoma City and is a testament to our clients to provide unsurpassed quality and innovative technical experience to their most important assets.”

About Cytovance Biologics
Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation.  In addition to its CGMP manufacturing services, the company offers process development, CGMP cell banking and support services from its Oklahoma City, Oklahoma facilities. The company’s approach couples considerable client-side experience with the necessary technical and operational expertise. We place significant value on customer service through communication, collaboration and flexibility.  Our customers receive unparalleled services that meet global regulatory standards and facilitate efficient completion of clinical development.  For more information on Cytovance, visit www.cytovance.com.

About Selexys Pharmaceuticals
Selexys is a biopharmaceutical company focused on the development of antibody based therapeutics for inflammatory and thrombotic diseases.  The Selexys “Selectin Inhibition” platform has yielded 2 human/humanized antibody drug candidates focused on the treatment of Crohn’s and sickle cell disease. For more information on Selexys visit www.selexys.com.